MDX-214

N/A

Report date: 2022/02/21 13:58:03

Base Information

Drug NameMDX-214

Drug Alias NameAnti-EGFr/CD89 antibody

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsIgA Fc receptor modulators

TargetsIgA Fc receptorEpidermal growth factor receptor erbB1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedarex Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedarex Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A